Role of CYP2C19 gene polymorphism in guidance of anti-platelet therapy after PCI
10.3969/j.issn.1008-0074.2017.05.09
- VernacularTitle:CYP2C19基因多态性对PCI术后抗血小板治疗的指导作用
- Author:
juan Yu YANG
1
;
Wei ZHANG
;
Zhe LI
;
ping Ya WANG
;
Jing BAI
;
Tao TIAN
Author Information
1. 陕西省人民医院心血管三科
- Keywords:
Polymorphism;
single nucleotide;
Thrombelastography;
Platelet aggregation inhibitors
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2017;26(5):493-496
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore guidance effect of CYP2C19 gene polymorphism on anti-platelet therapy after per-cutaneous coronary intervention (PCI).Methods:A total of 105 patients with coronary heart disease,who received clopidogrel after PCI,were selected.According to results of CYP2C19 gene polymorphism detection,they were di-vided into normal metabolism group (n=51,fast metabolism type)and poor metabolism group (n=54,medium and slow metabolism type).Platelet inhibition rate induced by adenyl diphosphoric acid (ADP)measured by throm-boelastogram (TEG)and clopidogrel resistance (CR)rate were analyzed and compared between two groups.Re-sults:Normal metabolism group and poor metabolism group occupied 48.57% and 51.43% respectively among the 105 patients (medium metabolism type and slow metabolism type occupied 43.81% and 7.62% respectively in poor metabolism group).Compared with normal metabolism group,there was significant reduction in platelet inhibition rate induced by ADP [(78.14 ± 17.86)% vs.(41.67 ± 12.05 )%] and significant rise in incidence rate of CR (11.76% vs.59.26%)in poor metabolism group,P =0.001 all.Conclusion:CYP2C19 gene polymorphism is an important influencing factor for clopidogrel resistance.Therapeutic effect of clopidogrel after PCI in normal metab-olism group is significantly better than that of poor metabolism group,therefore,CYP2C19 gene polymorphism de-tection is help to guide anti-platelet therapy after PCI.
